---
title: "免疫检查点的糖基化及其在肿瘤中的应用"
date: 2024-11-04T00:51:01Z
draft: ["false"]
tags: [
  "fetched",
  "东晓生物"
]
categories: ["Acdemic"]
---
免疫检查点的糖基化及其在肿瘤中的应用 by 东晓生物
------
<div><p><img data-ratio="0.4069627851140456" data-src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibRRictuEY3Uj7jLW3UZ7d8mibXhMmTj25iaBVhLdQxebRWVgCoqpljABBQ/640?wx_fmt=png" data-type="png" data-w="833" src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibRRictuEY3Uj7jLW3UZ7d8mibXhMmTj25iaBVhLdQxebRWVgCoqpljABBQ/640?wx_fmt=png"></p><p>影响因子：<span lang="EN-US">5.215<p></p></span></p><p>研究概述：<span lang="EN-US"><p></p></span></p><p>特异性糖蛋白可作为人类癌症的生物标志物。多数免疫检查点是膜糖蛋白，它们的糖基化可能改变免疫系统对肿瘤的感知，影响机体的抗肿瘤免疫。<span lang="EN-US"><p></p></span></p><p>本文讨论了肿瘤免疫中涉及的免疫检查点的糖基化修饰，介绍了小非编码<span lang="EN-US">RNA</span>的糖基化，以及糖基化靶向免疫治疗的最新进展。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">1</span>糖基化定义<span lang="EN-US"><p></p></span></strong></p><p><span lang="EN-US">PTM</span>（翻译后修饰）是指蛋白质中特定氨基酸残基的化学修饰，包括糖基化、磷酸化、甲基化、乙酰化、泛素化等过程，是影响蛋白质活性或表达水平的关键。糖基化是其中最丰富多样的一种，是调节多种生理和病理功能的重要细胞机制，包括<span lang="EN-US">14</span>个不同的类型：<span lang="EN-US">N-</span>糖基化、<span lang="EN-US">11</span>种<span lang="EN-US">O-</span>糖基化、<span lang="EN-US">C-</span>甘露糖基化和生成<span lang="EN-US">GPI</span>锚定蛋白，其中<span lang="EN-US">N-</span>糖基化和<span lang="EN-US">O-</span>糖基化最常见。</p><p><img data-ratio="0.6374549819927972" data-src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibSu5xxXOHqeXNMwP33Tj4uFq6SBAvdib0jeh7CEvB5VSLDRibCKGnmoiaQ/640?wx_fmt=png" data-type="png" data-w="833" src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibSu5xxXOHqeXNMwP33Tj4uFq6SBAvdib0jeh7CEvB5VSLDRibCKGnmoiaQ/640?wx_fmt=png"></p><p><strong><span lang="EN-US">2.</span>蛋白质糖基化的过程<span lang="EN-US"><p></p></span></strong></p><p>糖基化由复杂的生物合成途径产生，主要过程涉及：糖链通过糖基转移酶催化转移到蛋白质，在聚糖和氨基酸残基之间形成糖苷键。蛋白组装是通过一系列转运、糖链末端剪切、岩藻糖基化或唾液酸化完成的。大多数糖基化发生在内质网<span lang="EN-US">ER</span>，并在高尔基体结束。除黏蛋白型<span lang="EN-US">O-</span>糖基化外，从高尔基体开始的糖基化很少。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">2.1 N-</span>糖基化过程<span lang="EN-US"><p></p></span></strong></p><p>作为连接点，<span lang="EN-US">N -</span>糖基与天冬酰胺的酰胺基、<span lang="EN-US">N</span>末端氨基酸的<span lang="EN-US">α-</span>氨基以及赖氨酸或精氨酸的<span lang="EN-US">ω-</span>氨基形成<span lang="EN-US">N -</span>糖苷键。包含两个催化亚基<span lang="EN-US">SST3A</span>和<span lang="EN-US">STT3B</span>的多单元寡糖转移酶<span lang="EN-US">(OST)</span>复合物催化这一过程。这是真核细胞内质网中含量最多、保守性最好的蛋白修饰。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">ER</span>中错误折叠的蛋白质通过<span lang="EN-US">ER</span>相关降解<span lang="EN-US">(ERAD)</span>转移到细胞质基质中进行蛋白酶体降解。对<span lang="EN-US">ERAD</span>耐药的错误折叠蛋白因太大而无法穿过<span lang="EN-US">ER</span>膜，故被运送到内溶酶体进行<span lang="EN-US">ER-</span>溶酶体相关降解<span lang="EN-US">(ERLAD)</span>。这两种降解途径均被证明与<span lang="EN-US">N-</span>聚糖有关。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">2.2 O-</span>糖基化过程<span lang="EN-US"><p></p></span></strong></p><p><span lang="EN-US">O-</span>糖基化发生在高尔基体中，形成<span lang="EN-US">O-</span>糖苷键作为与丝氨酸、苏氨酸、羟赖氨酸和羟脯氨酸羟基的连接点，比<span lang="EN-US">N-</span>糖基化更直接、更不均匀。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">O-GlcNA</span>酰化，也称为黏蛋白型<span lang="EN-US">O-</span>糖基化，是最常见的类型。不太常见的类型包括<span lang="EN-US">O-</span>岩藻糖基化、<span lang="EN-US">O-</span>葡糖基化和<span lang="EN-US">O-</span>甘露糖基化。许多蛋白质被可逆的<span lang="EN-US">O-</span>糖基化修饰，如转录因子、细胞骨架蛋白、癌基因和激酶。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">O-GlcNAc</span>修饰由己糖胺生物合成途径<span lang="EN-US">(HBP)</span>的终产物尿二磷酸<span lang="EN-US">N-</span>乙酰葡萄糖胺<span lang="EN-US">(UDP-GlcNAc)</span>实现的。<span lang="EN-US">O-GlcNAc</span>转移酶<span lang="EN-US">(OGT)</span>的活性介导蛋白质的<span lang="EN-US">O-GlcNAc</span>酰化，去除聚糖的酶是<span lang="EN-US">β-N-</span>乙酰氨基葡萄糖苷酶<span lang="EN-US">(OGA)</span>。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">O-</span>糖基化黏蛋白在一系列肿瘤细胞类型中表达，并通过调节蛋白稳定性诱导各种致癌信号分子促进肿瘤进展。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3. N-</span>糖基化免疫检查点<span lang="EN-US"><p></p></span></strong></p><p>图<span lang="EN-US">2</span>总结了免疫细胞和肿瘤细胞表面受糖基化调控的免疫受体和配体。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US"><img data-ratio="0.8640132669983416" data-src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibenjCSVSVWG9icZfoibhhIxEP66008ia0gqiajC2pwKFC7DP3pvaxlamSJQ/640?wx_fmt=png" data-type="png" data-w="603" src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibenjCSVSVWG9icZfoibhhIxEP66008ia0gqiajC2pwKFC7DP3pvaxlamSJQ/640?wx_fmt=png"></span><span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1 B7-CD28</span>超家族<span lang="EN-US"><p></p></span></strong></p><p>它属于共刺激分子家族，相关通路既可以提供激动信号来增强和维持、也可以提供抑制信号来抑制<span lang="EN-US">T</span>细胞免疫应答。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.1 <span></span>CD28</span>和<span lang="EN-US">CD80/CD86<p></p></span></strong></p><p><span lang="EN-US">B7-CD28</span>超家族中最早和最重要的共刺激分子是<span lang="EN-US">CD28</span>和<span lang="EN-US">CD80/CD86</span>。<span lang="EN-US">CD28</span>是在<span lang="EN-US">T</span>淋巴细胞表面发现的一种糖蛋白，与<span lang="EN-US">CD80 (B7-1)</span>和<span lang="EN-US">CD86 (B7-2)</span>结合。<span lang="EN-US"><p></p></span></p><p>当<span lang="EN-US">CD28 N-</span>糖基化位点突变或糖苷酶抑制剂减少<span lang="EN-US">N-</span>糖基化时，<span lang="EN-US">CD28-CD80</span>的结合显著增加，下游信号激活被放大，表明<span lang="EN-US">N-</span>糖基化负调控<span lang="EN-US">CD28</span>功能。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.2<span></span>CTLA-4</span>（<span lang="EN-US">CD152</span>）<span lang="EN-US"><p></p></span></strong></p><p><span lang="EN-US">(</span>细胞毒性<span lang="EN-US">T</span>淋巴细胞相关蛋白<span lang="EN-US">4)</span>，通常称<span lang="EN-US">CD152</span>，是<span lang="EN-US">CD28</span>的同源物，但它与<span lang="EN-US">CD80/CD86 (B7-1/2)</span>结合的亲和力高于<span lang="EN-US">CD28</span>。<span lang="EN-US">CTLA-4</span>是一种表达在<span lang="EN-US">T</span>细胞上的免疫检查点受体，与<span lang="EN-US">CD28</span>竞争结合位点，导致免疫应答下调。<span lang="EN-US"><p></p></span></p><p>它受糖基化调节，<span lang="EN-US">N-</span>聚糖数目和支链会影响其细胞表面水平。<span lang="EN-US">TCR</span>信号通路上调<span lang="EN-US">CTLA-4</span>表面表达，通过己糖胺和<span lang="EN-US">N-</span>聚糖分支通路影响<span lang="EN-US">T</span>细胞功能。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.3<span></span>PD-1/PD-L1<p></p></span></strong></p><p>程序性细胞死亡蛋白<span lang="EN-US">-1 (PD-1)/</span>程序性死亡配体<span lang="EN-US">1 (PD-L1)</span>是已确定的主要免疫检查点之一，抑制或阻断<span lang="EN-US">PD-1/PD-L1</span>通路可显著增强<span lang="EN-US">T</span>细胞介导的免疫杀伤活性，从而增强抗肿瘤作用。<span lang="EN-US"><p></p></span></p><p><strong>糖基化对<span lang="EN-US">PD-1</span>和<span lang="EN-US">PD-L1</span>的相互作用至关重要。</strong><span lang="EN-US">PD-1</span>核心岩藻糖基化<span lang="EN-US">N</span>聚糖的<span lang="EN-US">N49</span>和<span lang="EN-US">N74</span>被确定为抑制焦点转移酶<span lang="EN-US">8 (Fut8)</span>的关键位置，可降低<span lang="EN-US">PD-1</span>表达，增强<span lang="EN-US">T</span>细胞活化。<span lang="EN-US">PD-1</span>在<span lang="EN-US">T</span>细胞中<span lang="EN-US">N49</span>、<span lang="EN-US">N58</span>、<span lang="EN-US">N74</span>和<span lang="EN-US">N116</span>位点高度<span lang="EN-US">N-</span>糖基化，特别是<span lang="EN-US">N58</span>。当<span lang="EN-US">T</span>细胞被激活时，<span lang="EN-US">PD-1</span>的糖型如聚<span lang="EN-US">LacNAc</span>和核心岩藻糖基化上调。<span lang="EN-US">β-1,3-N-</span>乙酰葡糖胺基转移酶<span lang="EN-US"> (B3GNT3)</span>和<span lang="EN-US">FUT8</span>分别催化聚<span lang="EN-US">LacNAc</span>和核心岩藻糖的合成。<span lang="EN-US"><p></p></span></p><p><strong>糖基化还调节癌症干细胞<span lang="EN-US">(CSCs)</span>中<span lang="EN-US">PD-L1</span>的表达。</strong><span lang="EN-US">N-</span>糖基转移酶<span lang="EN-US">STT3</span>通过<span lang="EN-US">β-</span>连环蛋白被上皮<span lang="EN-US">-</span>间充质转化<span lang="EN-US">(EMT)</span>上调，诱导<span lang="EN-US">PD-L1-N -</span>糖基化调节<span lang="EN-US">PD-L1</span>在<span lang="EN-US">CSCs</span>中的积累，从而促进免疫逃避。它的高表达与结肠癌患者预后不良有关。<span lang="EN-US">KYA1797K</span>是结肠癌中的抑癌基因，通过抑制<span lang="EN-US">β-catenin/STT3</span>信号通路抑制<span lang="EN-US">PD-L1 N-</span>糖基化和结肠<span lang="EN-US">CSCs</span>的免疫逃避，这为结肠癌免疫治疗开辟了新的可能性。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">N-</span>糖基化在维持蛋白质稳定性方面起关键作用。</strong>不完全糖基化的<span lang="EN-US">PD-1</span>也受泛素化的调控。<span lang="EN-US">KLHL22</span>是<span lang="EN-US">PD-1</span>的<span lang="EN-US">E3</span>连接酶衔接子，在其膜定位之前诱导不完全糖基化的<span lang="EN-US">PD-1</span>降解。<span lang="EN-US">KLHL22</span>下调抑制<span lang="EN-US">T</span>细胞活化和抗肿瘤反应。非糖基化的<span lang="EN-US">PD-L1</span>稳定性较差，可与糖原合成酶激酶<span lang="EN-US">3β (GSK3β)</span>结合，磷酸化后被泛素<span lang="EN-US">/</span>蛋白酶体系统降解。<span lang="EN-US">EGF</span>信号诱导的<span lang="EN-US">PD-L1</span>糖基化可阻碍<span lang="EN-US">GSK3β</span>与<span lang="EN-US">PD-L1</span>相互作用，稳定<span lang="EN-US">PD-L1</span>并增强其免疫抑制活性。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">EGFR</span>小分子抑制剂吉非替尼可抑制<span lang="EN-US">EGF</span>信号通路，使<span lang="EN-US">PD-L1</span>不稳定，增强抗肿瘤免疫。<span lang="EN-US">EGF</span>信号还通过上调<span lang="EN-US">B3GNT3</span>，促进三阴性乳腺癌<span lang="EN-US">(TNBC)</span>细胞中<span lang="EN-US">N192</span>和<span lang="EN-US">N200</span>位点的<span lang="EN-US">PD-L1N -</span>糖基化，使<span lang="EN-US">PD-L1</span>与细胞毒性<span lang="EN-US">T</span>细胞上的<span lang="EN-US">PD-1</span>相互作用，导致<span lang="EN-US">T</span>细胞衰竭。<span lang="EN-US"><p></p></span></p><p><strong>去糖基化<span lang="EN-US">PD-L1</span>的表达是预测<span lang="EN-US">PD-1</span>抑制剂疗效的重要生物标志物。</strong>检测<span lang="EN-US">PD-L1</span>的标准临床方法是免疫组化<span lang="EN-US">(IHC)</span>检查，<span lang="EN-US">PD-L1</span>表达越高，<span lang="EN-US">PD-1</span>抑制剂的疗效可能越好。然而部分低表达或无表达<span lang="EN-US">PD-L1</span>的患者对<span lang="EN-US">PD-L1</span>抑制剂也有反应，这可能与<span lang="EN-US">PD-L1</span>的糖基化状态有关。虽然<span lang="EN-US">PD-L1</span>高度糖基化，但临床上用于检测<span lang="EN-US">PD-L1</span>的诊断抗体不能有效识别糖基化的<span lang="EN-US">PD-L1</span>，导致<span lang="EN-US">PD-L1</span>的<span lang="EN-US">IHC</span>检查出现假阴性。用肽<span lang="EN-US">-N-</span>糖苷酶<span lang="EN-US">F (PNGase F)</span>去除福尔马林固定石蜡包埋中的肿瘤块，然后进行<span lang="EN-US">IHC</span>，检测灵敏度显著提高。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.4<span></span>PD-L2</span>和<span lang="EN-US">PD-1<p></p></span></strong></p><p><span lang="EN-US">PD-L2</span>（<span lang="EN-US">CD273</span>或<span lang="EN-US">B7-DC</span>），是与<span lang="EN-US">PD-1</span>结合的第二个重要配体。该结合抑制<span lang="EN-US">T</span>细胞活化。<span lang="EN-US">PD-L2</span>表达水平可作为预测抗<span lang="EN-US">PD-1</span>治疗临床疗效的补充信息。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">PD-L2</span>在<span lang="EN-US">N64</span>、<span lang="EN-US">N157</span>、<span lang="EN-US">N163</span>和<span lang="EN-US">N189</span>位点被<span lang="EN-US">STAT3FUT8</span>介导<span lang="EN-US">N -</span>糖基化，并在西妥昔单抗耐药头颈部鳞状细胞癌<span lang="EN-US">(HNSCC)</span>中过表达。在<span lang="EN-US">HNSCC</span>体内模型中，抑制<span lang="EN-US">PD-L2</span>糖基化可降低表皮生长因子受体<span lang="EN-US">(EGFR)</span>阻滞剂西妥昔单抗的耐药性，糖基化水平可预测抗<span lang="EN-US">EGFR</span>疗效。<span lang="EN-US"><p></p></span></p><p>此外，<span lang="EN-US">N-</span>糖基化通过阻断泛素化介导的溶酶体降解来维持<span lang="EN-US">PD-L2</span>稳定性。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">PD-1</span>和<span lang="EN-US">PD-L1/2</span>结合和与糖基化相关的降解机制如图<span lang="EN-US">3</span>所示。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US"><img data-ratio="1.0277456647398844" data-src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibCcKq1NGdl3Itp8cKrEOj8nib1h3AUK8sQn9ybNZfCHXjADngyl2xluw/640?wx_fmt=png" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNibCcKq1NGdl3Itp8cKrEOj8nib1h3AUK8sQn9ybNZfCHXjADngyl2xluw/640?wx_fmt=png"></span><span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.5<span></span>ICOS/ICOSL<p></p></span></strong></p><p>共刺激因子<span lang="EN-US">(ICOS)</span>与<span lang="EN-US">ICOSL(B7-H2)</span>结合，提供共刺激信号激活<span lang="EN-US">T</span>细胞。在<span lang="EN-US">ICOS</span>中存在推测性的<span lang="EN-US">N</span>连接糖基化位点：<span lang="EN-US">N89</span>连接的糖基化使<span lang="EN-US">ICOS</span>保持稳定并将其运送到细胞表面膜；<span lang="EN-US">N110</span>糖基化位点在<span lang="EN-US">ICOS-L</span>结合中很关键，敲低<span lang="EN-US">N110</span>位点可使其与<span lang="EN-US">ICOSL</span>的结合亲和力提高<span lang="EN-US">4.3</span>倍。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.6<span></span>B7-H3 (CD276)</span>、<span lang="EN-US">B7-H4 (B7x/B7S1)</span>、<span lang="EN-US">HHLA2</span>和<span lang="EN-US">TMIGD2</span></strong><span lang="EN-US"><p></p></span></p><p><span lang="EN-US">B7-H3</span>在多种肿瘤中表达，抑制<span lang="EN-US">B7-H3</span>可以防止肿瘤的形成。<span lang="EN-US">B7-H3</span>在口腔鳞状细胞癌的肿瘤细胞和<span lang="EN-US">APC</span>中显著过表达，与正常口腔上皮细胞相比，肿瘤细胞表面的<span lang="EN-US">B7-H3</span>高度岩藻糖基化，<span lang="EN-US">N-</span>糖基化异常。研究发现：<span lang="EN-US">FUT8</span>催化<span lang="EN-US">B7-H3 N -</span>聚糖的核心岩藻糖基化，以维持其高表达和稳定性，从而促进免疫抑制。<span lang="EN-US"><p></p></span></p><p>同样<span lang="EN-US">B7-H4</span>作为一种共抑制配体，在免疫冷肿瘤中高表达，并与<span lang="EN-US">PD-L1</span>表达呈负相关。<span lang="EN-US">B7-H4</span>的<span lang="EN-US">N-</span>连接糖基化通过阻止<span lang="EN-US">B7-H4</span>的泛素化来保持稳定性。抑制<span lang="EN-US">B7-H4</span>的<span lang="EN-US">N-</span>糖基化使免疫冷肿瘤转变为免疫热肿瘤，可增加对免疫治疗的反应。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.1.7<span></span>NK</span>细胞上表达的受体<span lang="EN-US"><p></p></span></strong></p><p>与<span lang="EN-US">T</span>细胞不同，<span lang="EN-US">NK</span>细胞是淋巴细胞，能在无预先致敏的情况下破坏肿瘤细胞。成熟<span lang="EN-US">NK</span>细胞表达多种激活受体，其中最重要的是天然细胞毒性受体<span lang="EN-US">(NCRs)</span>，包括<span lang="EN-US">NKp30</span>、<span lang="EN-US">NKp44</span>和<span lang="EN-US">NKp46</span>。<span lang="EN-US">NKp30</span>是与<span lang="EN-US">B7-H6</span>结合的<span lang="EN-US">NK</span>细胞的主要激活受体。它的茎结构域是配体结合所必需的，其差异糖基化影响配体结合的亲和力，从而影响下游的细胞内信号。此外，<span lang="EN-US">NKp30</span>外膜有三个不同的位点<span lang="EN-US">(N42</span>、<span lang="EN-US">N69</span>和<span lang="EN-US">N121)</span>被<span lang="EN-US">N</span>糖基化，有研究报道<span lang="EN-US">N</span>糖基化是<span lang="EN-US">NKp30</span>寡聚的关键。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2<span></span>B7</span>超家族外的免疫检查点<span lang="EN-US"><p></p></span></strong></p><p>除了<span lang="EN-US">CD28/B7</span>超家族外，免疫细胞、肿瘤细胞和免疫抑制骨髓细胞表达的各种<strong>共抑制受体</strong>也可以被<span lang="EN-US">N-</span>糖基化控制。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.1<span></span>LAG-3<p></p></span></strong></p><p>淋巴细胞活化基因<span lang="EN-US">-3 (LAG-3)</span>是一种在<span lang="EN-US">T</span>细胞中表达的<span lang="EN-US">I</span>型跨膜蛋白，具有四个结构域。其细胞外结构域与<span lang="EN-US">CD4</span>相似，可与<span lang="EN-US">CD4</span>竞争结合<span lang="EN-US">MHCII</span>抑制<span lang="EN-US">T</span>细胞活化。<span lang="EN-US"><p></p></span></p><p>多项研究表明，在多种人类肿瘤类型中，<span lang="EN-US">LAG-3</span>的高水平表达与肿瘤生长和预后之间存在相关性。<span lang="EN-US">LAG-3</span>高度糖基化在<span lang="EN-US">D2-D4</span>结构域有多个<span lang="EN-US">N-</span>糖基化位点，有报道<span lang="EN-US">LAG-3</span>可与<span lang="EN-US">Galectin-3</span>或肝窦内皮细胞凝集素<span lang="EN-US">(LSECtin)</span>相互作用，其结合位点为<span lang="EN-US">LAG-3</span>上的聚糖。然而，<span lang="EN-US">LAG-3</span>糖基化是否与肿瘤免疫相关尚不清楚。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.2<span></span>TIGIT<p></p></span></strong></p><p>具有免疫球蛋白和<span lang="EN-US">ITIM</span>结构域的<span lang="EN-US">T</span>细胞免疫受体<span lang="EN-US">(TIGIT)</span>是<span lang="EN-US">T</span>细胞和<span lang="EN-US">NK</span>细胞上表达的另一种重要的免疫抑制受体，包含三个配体，其中在肿瘤细胞和<span lang="EN-US">APC</span>中表达的<span lang="EN-US">PVR (CD155)</span>是<span lang="EN-US">TIGIT</span>的主要配体，具有较高亲和力。<span lang="EN-US">TIGIT</span>最终通过与<span lang="EN-US">PVR</span>结合以及随后的一系列反应抑制抗肿瘤免疫。<span lang="EN-US"><p></p></span></p><p>研究发现两个<span lang="EN-US">N-</span>糖基化位点<span lang="EN-US">N32</span>和<span lang="EN-US">N101</span>，其中<span lang="EN-US">N101</span>对<span lang="EN-US">PVR</span>和<span lang="EN-US">TIGIT</span>相互作用的影响更显著。<span lang="EN-US">TIGIT</span>的<span lang="EN-US">N -</span>糖基化在维持<span lang="EN-US">TIGIT</span>和<span lang="EN-US">PVR</span>之间的相互作用是必要的，这可能是免疫治疗的潜在靶点。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.3<span></span>4-1BB (CD137/TNFRSF9)<p></p></span></strong></p><p>这是一种可诱导的肿瘤坏死因子受体<span lang="EN-US">(TNFR)</span>超家族成员，在免疫系统的各种细胞尤其是<span lang="EN-US">T</span>细胞中表达。晶体结构显示<span lang="EN-US">4-1BB</span>与其配体<span lang="EN-US">4-1BBL/CD137L/TNFSF9</span>通过富半胱氨酸结构域<span lang="EN-US">(CRD) 2</span>和<span lang="EN-US">3</span>相互作用，促进免疫细胞的激活和增殖。<span lang="EN-US"><p></p></span></p><p>研究发现，<span lang="EN-US">4-1BB</span>的胞外结构域在<span lang="EN-US">CRD4</span>上有两个糖基化位点<span lang="EN-US">(N138</span>和<span lang="EN-US">N149)</span>，证实<span lang="EN-US">N-</span>糖基化与<span lang="EN-US">4-1BB/4-1BBL</span>结合无关。此外，<span lang="EN-US">N-</span>糖基化通过维持其寡聚性来促进<span lang="EN-US">4-1BB</span>膜的定位。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.4<span></span>TIM-3/Gal-9<p></p></span></strong></p><p><span lang="EN-US">T</span>细胞免疫球蛋白和粘蛋白结构域<span lang="EN-US">-3(TIM-3)</span>是一种活化诱导的抑制性受体，并与其配体半乳糖凝集素<span lang="EN-US">-9 (Gal-9)</span>结合，在癌症中诱导免疫耐受和<span lang="EN-US">T</span>细胞衰竭。同时，<span lang="EN-US">PD-1</span>和<span lang="EN-US">TIM-3</span>在<span lang="EN-US">T</span>细胞上的共表达与癌症中的<span lang="EN-US">T</span>细胞衰竭有关。<span lang="EN-US"><p></p></span></p><p>报道称<span lang="EN-US">Gal-9</span>与<span lang="EN-US">TIM-3</span>上的碳水化合物链结合，经重组糖苷酶<span lang="EN-US">(PNGase F)</span>处理的<span lang="EN-US">TIM-3</span>不能与<span lang="EN-US">Gal-9</span>结合，提示糖基化调控了两者的结合。此外，共表达<span lang="EN-US">PD-1</span>与<span lang="EN-US">TIM-3</span>偶联形成异二聚体，<span lang="EN-US">Gal-9</span>交联这些二聚体形成凝集素<span lang="EN-US">/</span>糖蛋白晶格，从而阻断<span lang="EN-US">TIM-3/Gal-9</span>诱导的<span lang="EN-US">T</span>细胞死亡。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.5<span></span>Siglec-15<p></p></span></strong></p><p>唾液酸结合免疫球蛋白样凝集素<span lang="EN-US">(Siglec)</span>家族作为一种抑制性受体，通过识别唾液酸聚糖来塑造免疫抑制性肿瘤微环境。<span lang="EN-US">Siglec-15</span>不同于其他<span lang="EN-US">Siglec</span>家族成员，与<span lang="EN-US">B7- H1</span>等<span lang="EN-US">B7</span>家族成员有<span lang="EN-US">30%</span>以上的同源性，但其表达与<span lang="EN-US">B7- H1</span>无关。<span lang="EN-US">Siglec-15</span>在人类癌细胞和肿瘤相关巨噬细胞<span lang="EN-US">/</span>髓系细胞中上调，在<span lang="EN-US">N172</span>位点上被<span lang="EN-US">N</span>连接糖基化，从而减少其溶酶体依赖性降解，促进其细胞膜定位。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.6<span></span>“</span>别吃我<span lang="EN-US">”</span>信号蛋白<span lang="EN-US">CD47</span>、<span lang="EN-US">CD24<p></p></span></strong></p><p>肿瘤细胞可在细胞膜上表达<span lang="EN-US">CD47</span>、<span lang="EN-US">CD24</span>等<span lang="EN-US">“</span>别吃我<span lang="EN-US">”</span>信号蛋白，以避免巨噬细胞的吞噬，实现免疫逃逸。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">CD47</span>又称整合素相关蛋白<span lang="EN-US">(IAP)</span>或抗原表面决定蛋白<span lang="EN-US">OA3</span>，是一种广泛表达于肿瘤细胞的具有免疫球蛋白样结构的糖蛋白，与巨噬细胞表面的信号调节蛋白<span lang="EN-US">α (SIRP</span>α<span lang="EN-US">)</span>结合，产生一系列抑制巨噬细胞吞噬作用的级联反应。研究发现<span lang="EN-US">CD47</span>上有<span lang="EN-US">6</span>个可能的<span lang="EN-US">N-</span>糖基化位点，去除这些位点会改变<span lang="EN-US">CD47</span>的表达，然而<span lang="EN-US">N-</span>糖基化是否影响<span lang="EN-US">CD47/SIRPα</span>结合和肿瘤免疫逃避仍不清楚。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">CD24</span>与<span lang="EN-US">CD47</span>相似，在肿瘤细胞表面高度糖基化，与<span lang="EN-US">TAMs</span>上高表达的抑制受体<span lang="EN-US">Siglec-10</span>作用，从而抑制巨噬细胞的吞噬作用。有研究建立了<span lang="EN-US">Siglec-10/</span>唾液聚糖复合物的<span lang="EN-US">3D</span>模型，发现<span lang="EN-US">Siglec-10</span>倾向于将底物上的唾液化复合物型<span lang="EN-US">N-</span>聚糖结合。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">3.2.7<span></span>NK</span>细胞上表达的受体<span lang="EN-US"><p></p></span></strong></p><p><span lang="EN-US">NK</span>细胞的另一种激活受体是自然杀伤基团<span lang="EN-US">2D(NKG2D)</span>，是表达在<span lang="EN-US">NK</span>细胞表面的同型二聚体。由于细胞应激和<span lang="EN-US">DNA</span>损伤，<span lang="EN-US">MHC</span>类<span lang="EN-US">I</span>多肽相关序列<span lang="EN-US">A (MICA)</span>和<span lang="EN-US">MHC</span>类<span lang="EN-US">I</span>多肽相关序列<span lang="EN-US">B (MICB)</span>在肿瘤细胞表面表达，可与<span lang="EN-US">NKG2D</span>结合诱导免疫应答。肿瘤通过<span lang="EN-US">MICA</span>蛋白的蛋白水解脱落来逃避免疫监视。对于细胞膜表面表达，由某些<span lang="EN-US">MICA</span>等位基因表达的胞外结构域蛋白的<span lang="EN-US">N-</span>糖基化至关重要。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">2B4 (CD244)</span>是信号通路淋巴细胞活化分子相关受体家族中的一种细胞表面糖蛋白，在所有<span lang="EN-US">NK</span>细胞、<span lang="EN-US">CD8+ T</span>细胞和树突状细胞上均有表达，参与<span lang="EN-US">NK</span>细胞和<span lang="EN-US">T</span>细胞功能的调节。<span lang="EN-US">CD48</span>作为<span lang="EN-US">2B4</span>的配体在造血细胞表面表达，两者的结合对于细胞<span lang="EN-US">-</span>细胞相互作用至关重要。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">2B4</span>经<span lang="EN-US">N-</span>和<span lang="EN-US">O -</span>糖基化修饰高度唾液酸化，用糖苷酶去除<span lang="EN-US">N-</span>聚糖会显著抑制<span lang="EN-US">2B4</span>与<span lang="EN-US">CD48</span>的结合。从<span lang="EN-US">NK</span>细胞表面去除唾液酸或抑制<span lang="EN-US">O-</span>连接糖基化可增加<span lang="EN-US">2B4/CD48</span>结合，从而促进<span lang="EN-US">NK</span>细胞活化。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">4.<span></span>O-</span>糖基化免疫检查点<span lang="EN-US"><p></p></span></strong></p><p><span lang="EN-US">O-</span>糖基化促进肿瘤生长和发展。<span lang="EN-US">TIM-3</span>是粘蛋白型<span lang="EN-US">O-</span>糖基化，是<span lang="EN-US">Gal-9</span>结合所必需的，但其是否在肿瘤的诊断和治疗中起作用尚不清楚。丝氨酸和苏氨酸是糖基化过程中不可缺少的两个环节。通过<span lang="EN-US">O-</span>糖基化对富含丝氨酸<span lang="EN-US">/</span>精氨酸的蛋白激酶<span lang="EN-US">2(SRPK2)</span>进行翻译后修饰，可促进乳腺癌细胞在体外和体内的生长。<span lang="EN-US"><p></p></span></p><p>此外，已证实<span lang="EN-US">O-</span>糖基化磷酸甘油酸激酶<span lang="EN-US">1(PGK1)</span>增强糖酵解途径。糖基化修饰通过诱导<span lang="EN-US">PGK1</span>的线粒体易位抑制线粒体内三羧酸<span lang="EN-US">(TCA)</span>循环，从而促进结肠癌的增殖和生长。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">5.<span></span></span>糖基化<span lang="EN-US">-RNA<p></p></span></strong></p><p>最近研究表明<span lang="EN-US">RNA</span>可能被用作蛋白质或脂质之外的第三个糖基化靶点。新发现的可被糖基化的<span lang="EN-US">RNA</span>是一种小的、保守的非编码<span lang="EN-US">RNA</span>，称为<span lang="EN-US">“GlycoRNA”</span>，通常位于细胞质中，包括<span lang="EN-US">snRNA</span>、<span lang="EN-US">snoRNA</span>、<span lang="EN-US">miRNA</span>、<span lang="EN-US">siRNA</span>、<span lang="EN-US">piRNA</span>、<span lang="EN-US">stRNA</span>等。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">GlycoRNA</span>以富含唾液酸和岩藻糖的<span lang="EN-US">N-</span>聚糖为特征，其化学合成的具体途径尚不清楚，但很可能与蛋白质<span lang="EN-US">N-</span>糖基化的方式大致相同，甚至需要一些相同的酶。它出现在胞外膜上，提示可能在信号转导中发挥作用。由于唾液酸含量丰富，<span lang="EN-US">GlycoRNA</span>与两种唾液酸结合免疫球蛋白样凝集素<span lang="EN-US">(Siglecs)</span>结合，被认为是<span lang="EN-US">Siglec</span>家族的潜在配体。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US">GlycoRNA</span>已在各种人类细胞系中被检测到，并且这些特定细胞上的<span lang="EN-US">RNA</span>已被发现与各种自身免疫性疾病相关的小<span lang="EN-US">RNA</span>相同，因此其有可能与免疫系统相关。<span lang="EN-US"><p></p></span></p><p><strong><span lang="EN-US">6.<span></span></span>糖基化靶向免疫治疗的应用<span lang="EN-US"><p></p></span></strong></p><p>近年来，免疫疗法取得了巨大的进展。针对<span lang="EN-US">PD-1/PD-L1</span>的免疫检查点抑制抗体，包括帕博利珠单抗、纳武利尤单抗和阿替利珠单抗，尽管总体缓解率仍不高，但已显示出显著的临床获益。<span lang="EN-US"><p></p></span></p><p>大多数免疫检查点分子可以通过糖基化修饰。因此，免疫检查点分子的糖基化已成为肿瘤免疫治疗的一个有前途的靶点。针对糖基化的新药已经开发，正在进行体内外试验，一些药物已经开始临床试验。表<span lang="EN-US">1</span>是针对糖基化的新药物。<span lang="EN-US"><p></p></span></p><p><span lang="EN-US"><img data-ratio="0.7075208913649025" data-src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNib0ia7Sapgjicvn8HEMY5E9ibyXweBxu5KIdYA6N78O76kWVdDmlPtf3MAQ/640?wx_fmt=png" data-type="png" data-w="718" src="https://mmbiz.qpic.cn/mmbiz_png/3XJhvriakgjq1Rzypf2QXUGiaVbpYDweNib0ia7Sapgjicvn8HEMY5E9ibyXweBxu5KIdYA6N78O76kWVdDmlPtf3MAQ/640?wx_fmt=png"></span><span lang="EN-US"><p></p></span></p><p>总结：<span lang="EN-US"><p></p></span></p><p>没有共同核心结构的<span lang="EN-US">O-</span>糖基化比<span lang="EN-US">N-</span>糖基化更复杂，故现有研究大多着眼于<span lang="EN-US">N -</span>糖蛋白。此外发现<span lang="EN-US">RNA</span>可以通过糖基化修饰，使得<span lang="EN-US">RNA</span>成为除蛋白质和脂类外的第三个糖基化支架。<span lang="EN-US"><p></p></span></p><p>探索糖基化的分子机制将加深对肿瘤免疫的认识，深入研究免疫检查点分子的糖基化可能为肿瘤免疫治疗的临床应用提供更好的策略。</p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/1mCIeL1XDFgCU6RgYznfKg",target="_blank" rel="noopener noreferrer">原文链接</a>
